 Lays Martin Sobral
Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 11 | 2023 | 648 | 1.270 |
Why?
| | Mouth Neoplasms | 7 | 2020 | 93 | 1.220 |
Why?
| | Histone Chaperones | 5 | 2020 | 15 | 1.030 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 2 | 2020 | 64 | 0.700 |
Why?
| | Fibroblasts | 9 | 2011 | 1039 | 0.570 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 444 | 0.460 |
Why?
| | Antineoplastic Agents | 5 | 2020 | 2231 | 0.390 |
Why?
| | Cell Proliferation | 10 | 2020 | 2529 | 0.380 |
Why?
| | Myofibroblasts | 3 | 2011 | 149 | 0.370 |
Why?
| | Transcription Factors | 3 | 2017 | 1747 | 0.360 |
Why?
| | Doxorubicin | 2 | 2023 | 411 | 0.360 |
Why?
| | Head and Neck Neoplasms | 3 | 2017 | 569 | 0.360 |
Why?
| | DNA-Binding Proteins | 5 | 2020 | 1488 | 0.320 |
Why?
| | Gingiva | 4 | 2011 | 25 | 0.320 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 40 | 0.310 |
Why?
| | Stromal Cells | 5 | 2011 | 123 | 0.300 |
Why?
| | Peptides | 2 | 2020 | 1003 | 0.290 |
Why?
| | Activins | 2 | 2015 | 29 | 0.280 |
Why?
| | Nanoparticles | 2 | 2023 | 524 | 0.270 |
Why?
| | Smad7 Protein | 3 | 2011 | 20 | 0.270 |
Why?
| | MicroRNAs | 2 | 2020 | 694 | 0.270 |
Why?
| | Mouth Mucosa | 3 | 2017 | 85 | 0.260 |
Why?
| | Gingival Overgrowth | 2 | 2011 | 5 | 0.250 |
Why?
| | Skin Neoplasms | 2 | 2023 | 865 | 0.250 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2020 | 1457 | 0.250 |
Why?
| | Keratinocytes | 1 | 2017 | 249 | 0.230 |
Why?
| | Cyclosporine | 2 | 2011 | 257 | 0.230 |
Why?
| | Matrix Metalloproteinase 2 | 3 | 2011 | 58 | 0.230 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 708 | 0.210 |
Why?
| | Cell Survival | 6 | 2020 | 1111 | 0.210 |
Why?
| | Histones | 1 | 2020 | 672 | 0.210 |
Why?
| | Transforming Growth Factor beta1 | 5 | 2011 | 177 | 0.200 |
Why?
| | Mice, Nude | 4 | 2020 | 680 | 0.200 |
Why?
| | Matrix Metalloproteinases | 2 | 2011 | 95 | 0.200 |
Why?
| | Polyethyleneimine | 1 | 2023 | 19 | 0.200 |
Why?
| | Liquid Crystals | 1 | 2023 | 28 | 0.190 |
Why?
| | Neoplasms | 1 | 2019 | 2946 | 0.190 |
Why?
| | Cell Transdifferentiation | 3 | 2010 | 31 | 0.190 |
Why?
| | Lipids | 2 | 2023 | 723 | 0.190 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2023 | 141 | 0.180 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2014 | 222 | 0.180 |
Why?
| | Cell Line, Tumor | 6 | 2023 | 3565 | 0.160 |
Why?
| | PAX3 Transcription Factor | 1 | 2020 | 17 | 0.160 |
Why?
| | Connective Tissue Growth Factor | 5 | 2017 | 29 | 0.160 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2020 | 8 | 0.160 |
Why?
| | Skin | 1 | 2015 | 759 | 0.160 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 1 | 2020 | 26 | 0.160 |
Why?
| | Forkhead Box Protein O1 | 1 | 2020 | 35 | 0.160 |
Why?
| | Neoplasm Invasiveness | 5 | 2017 | 512 | 0.160 |
Why?
| | Mice, Inbred BALB C | 3 | 2020 | 1266 | 0.150 |
Why?
| | Rhabdomyosarcoma | 1 | 2020 | 65 | 0.150 |
Why?
| | Ameloblastoma | 1 | 2008 | 5 | 0.140 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2020 | 939 | 0.140 |
Why?
| | Polyethylene Glycols | 1 | 2023 | 649 | 0.140 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2020 | 212 | 0.140 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2014 | 889 | 0.140 |
Why?
| | Dihydropyridines | 1 | 2017 | 15 | 0.130 |
Why?
| | Tongue Neoplasms | 1 | 2007 | 26 | 0.130 |
Why?
| | Blotting, Western | 5 | 2017 | 1186 | 0.130 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2017 | 25 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 430 | 0.130 |
Why?
| | Annexin A1 | 1 | 2017 | 8 | 0.130 |
Why?
| | Paracrine Communication | 1 | 2007 | 67 | 0.130 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2017 | 79 | 0.130 |
Why?
| | Fibromatosis, Gingival | 2 | 2007 | 2 | 0.120 |
Why?
| | Retinal Pigment Epithelium | 1 | 2017 | 80 | 0.120 |
Why?
| | Transforming Growth Factor beta | 2 | 2007 | 475 | 0.120 |
Why?
| | Cell Line | 3 | 2020 | 2832 | 0.120 |
Why?
| | Bone Neoplasms | 1 | 2008 | 272 | 0.120 |
Why?
| | Neovascularization, Physiologic | 1 | 2017 | 197 | 0.120 |
Why?
| | Animals | 10 | 2023 | 38410 | 0.110 |
Why?
| | RNA, Neoplasm | 1 | 2015 | 83 | 0.110 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2007 | 340 | 0.110 |
Why?
| | Skin Absorption | 2 | 2023 | 14 | 0.110 |
Why?
| | Multigene Family | 1 | 2015 | 210 | 0.110 |
Why?
| | Gene Knockdown Techniques | 3 | 2020 | 334 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2017 | 980 | 0.100 |
Why?
| | Actins | 5 | 2011 | 428 | 0.100 |
Why?
| | Phenotype | 4 | 2020 | 3216 | 0.100 |
Why?
| | Down-Regulation | 4 | 2017 | 618 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 849 | 0.100 |
Why?
| | Humans | 23 | 2020 | 147293 | 0.100 |
Why?
| | Apoptosis | 5 | 2017 | 2454 | 0.100 |
Why?
| | Cofilin 1 | 1 | 2012 | 5 | 0.100 |
Why?
| | Adipose Tissue | 1 | 2017 | 646 | 0.090 |
Why?
| | Lymphatic Metastasis | 3 | 2015 | 338 | 0.090 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 445 | 0.090 |
Why?
| | Cell Movement | 1 | 2017 | 966 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2014 | 337 | 0.090 |
Why?
| | Mice | 7 | 2023 | 18491 | 0.090 |
Why?
| | Muscle, Smooth | 3 | 2011 | 153 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 2001 | 0.080 |
Why?
| | Protein Phosphatase 2 | 1 | 2020 | 41 | 0.080 |
Why?
| | Retinoblastoma Protein | 1 | 2020 | 62 | 0.080 |
Why?
| | Hydroxamic Acids | 1 | 2020 | 95 | 0.080 |
Why?
| | Ki-67 Antigen | 1 | 2020 | 120 | 0.080 |
Why?
| | Methylation | 1 | 2020 | 242 | 0.070 |
Why?
| | Drug Synergism | 1 | 2020 | 355 | 0.070 |
Why?
| | Cell Differentiation | 3 | 2020 | 2054 | 0.070 |
Why?
| | Gene Expression | 2 | 2017 | 1481 | 0.070 |
Why?
| | Immunohistochemistry | 3 | 2012 | 1730 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2011 | 891 | 0.060 |
Why?
| | Up-Regulation | 2 | 2017 | 848 | 0.060 |
Why?
| | Phosphorylation | 2 | 2012 | 1721 | 0.060 |
Why?
| | Smad2 Protein | 2 | 2011 | 37 | 0.060 |
Why?
| | Mitochondrial Dynamics | 1 | 2017 | 41 | 0.060 |
Why?
| | Cell Cycle | 2 | 2017 | 600 | 0.060 |
Why?
| | NF-kappa B | 1 | 2020 | 676 | 0.060 |
Why?
| | Disease-Free Survival | 2 | 2020 | 779 | 0.060 |
Why?
| | Iontophoresis | 1 | 2015 | 11 | 0.060 |
Why?
| | Proteomics | 1 | 2012 | 1203 | 0.060 |
Why?
| | Carcinogenesis | 1 | 2017 | 230 | 0.060 |
Why?
| | Administration, Topical | 1 | 2015 | 156 | 0.060 |
Why?
| | Collagen Type I | 2 | 2011 | 145 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2010 | 840 | 0.050 |
Why?
| | Cell Culture Techniques | 2 | 2011 | 375 | 0.050 |
Why?
| | Culture Media | 2 | 2017 | 161 | 0.050 |
Why?
| | Ultrasonic Waves | 1 | 2023 | 9 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2007 | 786 | 0.050 |
Why?
| | Administration, Cutaneous | 1 | 2023 | 127 | 0.050 |
Why?
| | Male | 9 | 2020 | 73950 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2014 | 365 | 0.050 |
Why?
| | Necrosis | 1 | 2014 | 245 | 0.050 |
Why?
| | Swine | 1 | 2015 | 828 | 0.050 |
Why?
| | NM23 Nucleoside Diphosphate Kinases | 1 | 2012 | 2 | 0.050 |
Why?
| | Fluorometry | 1 | 2012 | 19 | 0.050 |
Why?
| | DNA Fragmentation | 1 | 2012 | 43 | 0.050 |
Why?
| | Caspase 9 | 1 | 2012 | 55 | 0.050 |
Why?
| | Drug Carriers | 1 | 2023 | 137 | 0.050 |
Why?
| | Organelles | 1 | 2012 | 53 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2012 | 88 | 0.040 |
Why?
| | Child | 2 | 2019 | 22979 | 0.040 |
Why?
| | Cisplatin | 1 | 2014 | 347 | 0.040 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2012 | 55 | 0.040 |
Why?
| | Immunoassay | 1 | 2012 | 109 | 0.040 |
Why?
| | Antimetabolites | 1 | 2011 | 21 | 0.040 |
Why?
| | Bromodeoxyuridine | 1 | 2011 | 77 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 64 | 0.040 |
Why?
| | Caspase 3 | 1 | 2012 | 242 | 0.040 |
Why?
| | Female | 8 | 2023 | 80076 | 0.040 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 133 | 0.040 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 200 | 0.040 |
Why?
| | Membrane Microdomains | 1 | 2020 | 34 | 0.040 |
Why?
| | Glutathione | 1 | 2012 | 370 | 0.040 |
Why?
| | Anthracyclines | 1 | 2020 | 49 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1794 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2012 | 440 | 0.040 |
Why?
| | Aged | 5 | 2020 | 26514 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2023 | 381 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 319 | 0.040 |
Why?
| | Tretinoin | 1 | 2020 | 125 | 0.040 |
Why?
| | Prognosis | 2 | 2008 | 4383 | 0.040 |
Why?
| | Adult | 6 | 2020 | 41405 | 0.040 |
Why?
| | Transfection | 1 | 2011 | 930 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2020 | 191 | 0.040 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2008 | 25 | 0.040 |
Why?
| | Young Adult | 3 | 2020 | 14437 | 0.040 |
Why?
| | Bone Marrow | 1 | 2020 | 310 | 0.030 |
Why?
| | Antioxidants | 1 | 2012 | 550 | 0.030 |
Why?
| | Mitochondrial Size | 1 | 2017 | 4 | 0.030 |
Why?
| | Cytoplasm | 1 | 2008 | 255 | 0.030 |
Why?
| | Middle Aged | 5 | 2020 | 36821 | 0.030 |
Why?
| | Genes, myc | 1 | 2017 | 51 | 0.030 |
Why?
| | Colony-Forming Units Assay | 1 | 2017 | 95 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2017 | 75 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2625 | 0.030 |
Why?
| | Tongue | 1 | 2007 | 77 | 0.030 |
Why?
| | Luciferases | 1 | 2017 | 155 | 0.030 |
Why?
| | Luminescent Measurements | 1 | 2017 | 75 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 143 | 0.030 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2017 | 60 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2011 | 566 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2017 | 105 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1386 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2011 | 1172 | 0.030 |
Why?
| | Acyltransferases | 1 | 2017 | 78 | 0.030 |
Why?
| | Immediate-Early Proteins | 2 | 2007 | 46 | 0.030 |
Why?
| | Precancerous Conditions | 1 | 2007 | 166 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 287 | 0.030 |
Why?
| | Eye Diseases | 1 | 2017 | 98 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 1253 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2012 | 1368 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2007 | 376 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 984 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 318 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2015 | 240 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 1059 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1492 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 863 | 0.020 |
Why?
| | Signal Transduction | 2 | 2011 | 5272 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 481 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 110 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2011 | 2812 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 332 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2008 | 1339 | 0.020 |
Why?
| | Disease Progression | 1 | 2008 | 2890 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 2110 | 0.020 |
Why?
| | Adolescent | 2 | 2020 | 22825 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2012 | 728 | 0.020 |
Why?
| | Cytokines | 1 | 2017 | 2086 | 0.020 |
Why?
| | Collagen | 1 | 2010 | 460 | 0.020 |
Why?
| | Inflammation | 1 | 2017 | 2920 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2007 | 8430 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2006 | 1302 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 17560 | 0.010 |
Why?
| | Rats | 1 | 2010 | 5613 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2007 | 4169 | 0.010 |
Why?
|
|
Martin Sobral's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|